The SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit utilizes isothermal amplification for use in the analysis of SARS-CoV-2, the novel coronavirus that causes COVID-19. Colorimetric LAMP enables simple, visual detection (pink-to-yellow) of amplification of SARS-CoV-2 nucleic acid. Set up reactions quickly and easily, using a simple heat source and unique WarmStart® technology. The assay targets N and E regions of the SARS-CoV-2 genome, for optimized sensitivity and specificity.
Greg Patton, a development scientist at New England Biolabs, is one of the developers of the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, which was just released by NEB. In this video, Greg is going to tell us about how the kit works, what type of samples are compatible with it, and he’ll explain the kit’s intended uses.
As part of our COVID-19 Researcher Spotlight Series, in this video we are speaking with Nathan Tanner, who is a senior scientist at New England Biolabs. NEB’s products are available for research use only. However, we have been supporting customers who are working with these reagents to develop diagnostic tools and vaccines for the SARS-CoV-2 virus. Nathan has been involved in many of these collaborations, in addition to the development of NEB products that have been used in COVID-19 related research applications.
We have developed a highly sensitive RT-LAMP assay compatible with current reagents, that utilizes a colorimetric readout in as little as 30 minutes. In addition to this, we have developed an inexpensive pipeline to further increase sensitivity without requiring highly specialized equipment. A rapid inactivation protocol capable of inactivating virions, as well as endogenous nucleases, was also developed to increase sensitivity and sample stability.
This protocol, combined with our RT-LAMP assay, has a sensitivity of at least 50 viral RNA copies per microliter in a sample. To further increase the sensitivity, a purification protocol compatible with this inactivation method was developed. The inactivation and purification protocol, combined with our RT-LAMP assay, brings the sensitivity to at least 1 viral RNA copy per microliter in a sample.
We hope that this inactivation and purification pipeline, which costs approximately $0.07 per sample and which uses readily available reagents, will increase the availability of SARS-CoV-2 testing, as well as expand the settings in which this testing can be performed.
It has been suggested that population-scale testing can help break the cycle of isolation and spread, but current detection methods are not capable of such large-scale processing.
Here we propose LAMP-Seq, a barcoded Reverse-Transcription Loop-mediated Isothermal Amplification (RT-LAMP) protocol that could dramatically reduce the cost and complexity of population-scale testing. In this approach, individual samples are processed in a single heat step, producing barcoded amplicons that can be shipped to a sequencing center, pooled, and analyzed en masse.
Using unique barcode combinations per sample from a compressed barcode space enables extensive pooling, significantly reducing cost and organizational efforts. Given the low cost and scalability of next-generation sequencing, we believe that this method can be affordably scaled to analyze millions of samples per day using existing sequencing infrastructure.